Drug
Ravidasvir clinical trials
Also written PPI-668 and ASC16.
- studies test it
- 12
- open now
- 0
- in phase 3
- 3
- first study started
- 2011
How studies write it
Studies that test it under each name
Combined with it in one product
Studies by the year they started
12 studies that test it; most in 2013 (2)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 8
- Phase 2
- 4
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 2
Ascletis Pharmaceuticals Co., Ltd. (6) · Presidio Pharmaceuticals, Inc. (4) · Muhammad Radzi Abu Hassan (1) · Drugs for Neglected Diseases (1)
Often tested with
Tested in the same studies.
Danoprevir (4) · Sofosbuvir (3) · Ritonavir (2) · Ribavirin (2) · ASC18 (1) · Midazolam (1) · Omeprazole (1) · Telaprevir (1)
Studies
Open first, then newest update. How each study uses ravidasvir is read from its arms, and is right about nine times in ten.
Testing it · 12
- 8- Versus 12-week of Sofosbuvir-ravidasvir Treatment of Chronic Hepatitis CCompletedPhase 2/3Muhammad Radzi Abu HassanNCT04885855Written as Ravidasvir 200mg
- Strategic Transformation of the Market of HCV TreatmentsStatus unknownPhase 2/3Drugs for Neglected DiseasesNCT02961426Written as sofosbuvir + ravidasvir
- A Study of the Relative Bioavailability of ASC18 Tablets vs Reference Tablets in Healthy VolunteersCompletedPhase 1Ascletis Pharmaceuticals Co., Ltd.NCT04358523Written as ravidasvir and sofosbuvir
- Efficacy and Safety of Ravidasvir + Danoprevir/r 12-week Oral Therapy in Treatment-Naive Non Cirrhotic G1 CHC TaiwanCompletedPhase 2Ascletis Pharmaceuticals Co., Ltd.NCT03020095Written as Ravidasvir
- Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Virus Genotype1 Infected Subjects.CompletedPhase 2/3Ascletis Pharmaceuticals Co., Ltd.NCT03362814Written as Ravidasvir
- A Study to Evaluate the Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in ChinaCompletedPhase 1Ascletis Pharmaceuticals Co., Ltd.NCT03430830Written as Ravidasvir 50mg
- Pharmacokinetics and Safety of Ravidasvir and Danoprevir/r in Healthy Volunteers ChinaCompletedPhase 1Ascletis Pharmaceuticals Co., Ltd.NCT03020134Written as Ravidasvir
- Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in ChinaCompletedPhase 1Ascletis Pharmaceuticals Co., Ltd.NCT03288636Written as Ravidasvir
- Phase 1 Study of Relative Bioavailability of PPI-668 New Tablet Versus Capsule FormulationsCompletedPhase 1Presidio Pharmaceuticals, Inc.NCT02258321Written as PPI-668 tablet
- Phase 1 Study of Relative Bioavailability of PPI-668 Tablet and Capsule FormulationsCompletedPhase 1Presidio Pharmaceuticals, Inc.NCT01979484Written as PPI-668 capsule
- A Drug Interaction Study of the Effects of PPI-668 on the Pharmacokinetics of Midazolam and OmeprazoleCompletedPhase 1Presidio Pharmaceuticals, Inc.NCT01786382Written as PPI-668
- A Phase 1 Study of PPI-668 in Healthy Volunteers and Patients With Hepatitis C Virus (HCV) Genotype 1CompletedPhase 1Presidio Pharmaceuticals, Inc.NCT01448200Written as PPI-668
Given in every arm · 2 — ravidasvir is usual care beside what is tested
- A Study of the Efficacy and Safety of PPI-668 (NS5A Inhibitor) Plus Sofosbuvir, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype-4Status unknownPhase 2/3Pharco PharmaceuticalsNCT02371408Written as ravidasvir hydrochloride
- Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis CCompletedPhase 2Presidio Pharmaceuticals, Inc.NCT01859962Written as PPI-668
Codes
What other systems call ravidasvir · ClinicalTrials.gg INT000752
- UNII (FDA) AL3G001BI8RAVIDASVIRConfirmed FDA, Wikidata
- Wikidata Q25101668ravidasvirConfirmed FDA, Wikidata
- NCI Thesaurus C152158RavidasvirOne source FDA
- DrugBank DB15652One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | AL3G001BI8 | RAVIDASVIR | Confirmed FDA, Wikidata |
| Wikidata | Q25101668 | ravidasvir | Confirmed FDA, Wikidata |
| NCI Thesaurus | C152158 | Ravidasvir | One source FDA |
| DrugBank | DB15652 | — | One source Wikidata |
Also registered as ravidasvir hydrochloride (UNII HWN7376681).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.